FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1911252495> ?p ?o ?g. }

• W1911252495 endingPage "7" @default.
• W1911252495 startingPage "3920" @default.
• W1911252495 abstract "Bcl-2 is a negative prognostic indicator in prostate cancer, implicated in the development of androgen independence and treatment resistance, and is overexpressed in hormone-refractory prostate cancer (HRPC). Genasense is a phosphorothioate antisense oligonucleotide complementary to the bcl-2 mRNA open reading frame that in preclinical studies has shown significant activity in inhibiting expression of Bcl-2, delaying androgen independence, and improving chemosensitivity in prostate and other cancer models. In this dose escalation study, we evaluated the combination of Genasense and mitoxantrone, a standard chemotherapy for patients with HRPC.Twenty-six patients with HRPC were treated at seven dose levels receiving Genasense at a dose ranging from 0.6 to 5.0 mg/kg/day and mitoxantrone from 4 mg/m(2) to 12 mg/m(2). Genasense was administered as a 14-day i.v. continuous infusion every 28 days with mitoxantrone given as an i.v. bolus on day 8.No dose-limiting toxicities were observed. Hematological toxicities were transient and included neutropenia, thrombocytopenia, and lymphopenia. Nonhematological toxicities included fatigue, fever, nausea, arthralgias, myalgias, and transient elevations in serum creatinine, none of which were severe. Two patients had >50% reductions in prostate-specific antigen. One patient, who received six cycles of Genasense at 1.2 mg/kg/day and a low dose (4 mg/m(2)) of mitoxantrone, also had symptomatic improvement in bone pain. Peripheral blood lymphocyte Bcl-2 protein expression decreased in five of five patients given Genasense at 5mg/kg/day (mean change from baseline, -12.8%; SD, 16.4%) as assessed by flow cytometry. Serum concentrations of Genasense given at doses of 3 mg/kg/day and greater, exceeded 1 microg/ml.Genasense and mitoxantrone are well tolerated in combination, and mitoxantrone can be delivered at a standard dose with biologically active doses of Genasense without significant additional toxicity. This observation allays concerns about trials that combine Genasense with full doses of other cytotoxic agents seeking greater evidence of activity." @default.
• W1911252495 created "2016-06-24" @default.
• W1911252495 creator A5005231494 @default.
• W1911252495 creator A5011789895 @default.
• W1911252495 creator A5017551211 @default.
• W1911252495 creator A5023202154 @default.
• W1911252495 creator A5041164761 @default.
• W1911252495 creator A5060992997 @default.
• W1911252495 creator A5062125605 @default.
• W1911252495 creator A5076727746 @default.
• W1911252495 date "2001-12-01" @default.
• W1911252495 modified "2023-10-18" @default.
• W1911252495 title "A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer." @default.
• W1911252495 cites W1571487648 @default.
• W1911252495 cites W1591166893 @default.
• W1911252495 cites W1592603695 @default.
• W1911252495 cites W1821878109 @default.
• W1911252495 cites W1854708637 @default.
• W1911252495 cites W1893347245 @default.
• W1911252495 cites W1905989945 @default.
• W1911252495 cites W1911989431 @default.
• W1911252495 cites W1941582121 @default.
• W1911252495 cites W1968941811 @default.
• W1911252495 cites W1991441695 @default.
• W1911252495 cites W1991913775 @default.
• W1911252495 cites W1996146233 @default.
• W1911252495 cites W2014145760 @default.
• W1911252495 cites W2019187115 @default.
• W1911252495 cites W2034525338 @default.
• W1911252495 cites W2036274324 @default.
• W1911252495 cites W2049092816 @default.
• W1911252495 cites W2050667608 @default.
• W1911252495 cites W2058591356 @default.
• W1911252495 cites W2058917998 @default.
• W1911252495 cites W2075576299 @default.
• W1911252495 cites W2097663101 @default.
• W1911252495 cites W2106489628 @default.
• W1911252495 cites W2108494968 @default.
• W1911252495 cites W2109990295 @default.
• W1911252495 cites W2113211717 @default.
• W1911252495 cites W2146671198 @default.
• W1911252495 cites W2147730561 @default.
• W1911252495 cites W2162464751 @default.
• W1911252495 cites W2167805334 @default.
• W1911252495 cites W2255911290 @default.
• W1911252495 cites W2290539832 @default.
• W1911252495 cites W2403381121 @default.
• W1911252495 cites W3026227968 @default.
• W1911252495 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11751483" @default.
• W1911252495 hasPublicationYear "2001" @default.
• W1911252495 type Work @default.
• W1911252495 sameAs 1911252495 @default.
• W1911252495 citedByCount "50" @default.
• W1911252495 countsByYear W19112524952012 @default.
• W1911252495 countsByYear W19112524952013 @default.
• W1911252495 countsByYear W19112524952016 @default.
• W1911252495 countsByYear W19112524952022 @default.
• W1911252495 crossrefType "journal-article" @default.
• W1911252495 hasAuthorship W1911252495A5005231494 @default.
• W1911252495 hasAuthorship W1911252495A5011789895 @default.
• W1911252495 hasAuthorship W1911252495A5017551211 @default.
• W1911252495 hasAuthorship W1911252495A5023202154 @default.
• W1911252495 hasAuthorship W1911252495A5041164761 @default.
• W1911252495 hasAuthorship W1911252495A5060992997 @default.
• W1911252495 hasAuthorship W1911252495A5062125605 @default.
• W1911252495 hasAuthorship W1911252495A5076727746 @default.
• W1911252495 hasConcept C121608353 @default.
• W1911252495 hasConcept C126322002 @default.
• W1911252495 hasConcept C126894567 @default.
• W1911252495 hasConcept C143998085 @default.
• W1911252495 hasConcept C2776694085 @default.
• W1911252495 hasConcept C2777063308 @default.
• W1911252495 hasConcept C2780192828 @default.
• W1911252495 hasConcept C2780923524 @default.
• W1911252495 hasConcept C31760486 @default.
• W1911252495 hasConcept C71924100 @default.
• W1911252495 hasConcept C90924648 @default.
• W1911252495 hasConceptScore W1911252495C121608353 @default.
• W1911252495 hasConceptScore W1911252495C126322002 @default.
• W1911252495 hasConceptScore W1911252495C126894567 @default.
• W1911252495 hasConceptScore W1911252495C143998085 @default.
• W1911252495 hasConceptScore W1911252495C2776694085 @default.
• W1911252495 hasConceptScore W1911252495C2777063308 @default.
• W1911252495 hasConceptScore W1911252495C2780192828 @default.
• W1911252495 hasConceptScore W1911252495C2780923524 @default.
• W1911252495 hasConceptScore W1911252495C31760486 @default.
• W1911252495 hasConceptScore W1911252495C71924100 @default.
• W1911252495 hasConceptScore W1911252495C90924648 @default.
• W1911252495 hasIssue "12" @default.
• W1911252495 hasLocation W19112524951 @default.
• W1911252495 hasOpenAccess W1911252495 @default.
• W1911252495 hasPrimaryLocation W19112524951 @default.
• W1911252495 hasRelatedWork W1998107832 @default.
• W1911252495 hasRelatedWork W2006876985 @default.
• W1911252495 hasRelatedWork W2010765098 @default.
• W1911252495 hasRelatedWork W2054724578 @default.
• W1911252495 hasRelatedWork W2060708716 @default.
• W1911252495 hasRelatedWork W2153106027 @default.

• next